Cochrane Abstracts
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Immune Checkpoint Inhibitors (anti PD‐1 or Anti PD‐L1) Plus Platinum‐etoposide Versus Platinum‐etoposide Alone for First‐line Treatment of Extensive Small Cell Lung Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer.
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer. Accessed December 6, 2024.
Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer
Immune Checkpoint Inhibitors (anti PD‐1 or Anti PD‐L1) Plus Platinum‐etoposide Versus Platinum‐etoposide Alone for First‐line Treatment of Extensive Small Cell Lung Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 06]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer
ID - 433240
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433240/0/Immune_checkpoint_inhibitors__anti_PD‐1_or_anti_PD‐L1__plus_platinum‐etoposide_versus_platinum‐etoposide_alone_for_first‐line_treatment_of_extensive_small_cell_lung_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
